Your browser doesn't support javascript.
loading
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1.
Bhatt, Rupal S; Berjis, Abdulla; Konge, Julie C; Mahoney, Kathleen M; Klee, Alyssa N; Freeman, Samuel S; Chen, Chun-Hau; Jegede, Opeyemi A; Catalano, Paul J; Pignon, Jean-Christophe; Sticco-Ivins, Maura; Zhu, Baogong; Hua, Ping; Soden, Jo; Zhu, Jie; McDermott, David F; Arulanandam, Antonio R; Signoretti, Sabina; Freeman, Gordon J.
Afiliação
  • Bhatt RS; Department of Medicine, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. rbhatt@bidmc.harvard.edu gordon_freeman@dfci.harvard.edu.
  • Berjis A; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Konge JC; Department of Medicine, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Mahoney KM; Department of Medicine, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Klee AN; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Freeman SS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Chen CH; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Jegede OA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Catalano PJ; Department of Medicine, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Pignon JC; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Sticco-Ivins M; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Zhu B; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Hua P; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Soden J; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Zhu J; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • McDermott DF; Retrogenix, Chinley, High Peak, United Kingdom.
  • Arulanandam AR; BPS Bioscience, San Diego, California.
  • Signoretti S; Department of Medicine, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Freeman GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Cancer Immunol Res ; 9(2): 156-169, 2021 02.
Article em En | MEDLINE | ID: mdl-33229411
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoglobulinas / Carcinoma de Células Renais / Receptores KIR / Antígeno B7-H1 / Neoplasias Renais Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoglobulinas / Carcinoma de Células Renais / Receptores KIR / Antígeno B7-H1 / Neoplasias Renais Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article